Incyte Corp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INCYTE CORP
INCYTE CORP has four approved drugs.
There are forty-one US patents protecting INCYTE CORP drugs.
There are five hundred and ten patent family members on INCYTE CORP drugs in fifty-three countries and forty-seven supplementary protection certificates in nineteen countries.
Summary for Incyte Corp
| International Patents: | 510 |
| US Patents: | 41 |
| Tradenames: | 4 |
| Ingredients: | 2 |
| NDAs: | 4 |
| Patent Litigation for Incyte Corp: | See patent lawsuits for Incyte Corp |
| PTAB Cases with Incyte Corp as petitioner: | See PTAB cases with Incyte Corp as petitioner |
Drugs and US Patents for Incyte Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-002 | Nov 16, 2011 | RX | Yes | No | 10,016,429*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | 11,571,425 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Incyte Corp | JAKAFI XR | ruxolitinib phosphate | TABLET, EXTENDED RELEASE;ORAL | 217180-002 | May 1, 2026 | RX | Yes | No | 8,829,013*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-003 | Apr 17, 2020 | RX | Yes | Yes | 9,611,267 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | 8,415,362*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INCYTE CORP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg | ➤ Subscribe | 2015-12-17 |
International Patents for Incyte Corp Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Costa Rica | 20150265 | ⤷ Start Trial |
| Singapore | 10201503983Q | ⤷ Start Trial |
| Japan | 7887929 | ⤷ Start Trial |
| Taiwan | 201434835 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2020185532 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Incyte Corp Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1966202 | 8/2013 | Austria | ⤷ Start Trial | PRODUCT NAME: RUXOLITINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823 |
| 2455382 | PA2017012 | Lithuania | ⤷ Start Trial | PRODUCT NAME: RUKSOLITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/12/773/001-006 20150311 |
| 1966202 | 300574 | Netherlands | ⤷ Start Trial | PRODUCT NAME: RUXOLITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120828 |
| 2861595 | 21C1041 | France | ⤷ Start Trial | PRODUCT NAME: PEMIGATINIB OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1535 20210329 |
| 1966202 | 145 1-2013 | Slovakia | ⤷ Start Trial | FORMER OWNER: INCYTE CORPORATION, WILMINGTON, DE, US; |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
